EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Jubilant Pharmova revenue grew by 9% on a YoY basis to Rs. 1,822 crore in Q3 FY25, on the back of growth in revenue across all segments.
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics.
Q3 FY25 normalised PAT increased by 57% on a YoY basis to Rs. 104 crore on the back of improved operating performance and reduced finance cost. Net debt/EBITDA improved to 1.4x as on Dec’24 from 2.5x as on Mar’24.
Commenting on the Company’s performance, Shyam S. Bhartia, Chairman Jubilant Pharmova and Hari S. Bhartia, Co-Chairman & Non-Executive Director said, “We are pleased to announce solid revenue growth of 9% YoY on the back of growth across all business segments. EBITDA grew by 11% YoY to Rs. 296 crore, while reported PAT grew by 52% YoY to Rs. 101 crore. We repaid debt of US $125 million in the current financial year including US $25 million in Jan ’25. In the Radiopharmacy business, we started distribution of Pylarify, an industry leading prostate cancer diagnostic imaging agent from 2 of our PET radiopharmacies. We completed Media Fills on Line 3 in CDMO Sterile Injectables. The Drug Discovery business is driving increasing revenue from large pharma clients. We have also executed definitive agreements with Pierre Fabre to add strategic capabilities in the area of Biologics and Antibody drug conjugates. In the Generics business, we continue to focus on profitability.”
Subscribe To Our Newsletter & Stay Updated